Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 61 EBIT per Share is €-0.11 as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 61/100 and a GF Value™ of €2.17 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 76.36% on this metric.
Pangaea Oncology's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.11.
During the past 3 years, the average EBIT per Share Growth Rate was -11.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -17.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pangaea Oncology's EBIT per Share or its related term are showing as below:
XMAD:PANG'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -75.5 Med: 0.4 Max: 55.3
Current: -11.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Pangaea Oncology was 55.30% per year. The lowest was -75.50% per year. And the median was 0.40% per year.
XMAD:PANG's 3-Year EBIT Growth Rate is ranked worse than 76.36% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs XMAD:PANG: -11.90
Pangaea Oncology (XMAD:PANG) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pangaea Oncology EBIT per Share Related Terms
Pangaea Oncology EBIT per Share Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a EBIT per Share of €-0.11 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #126 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 76.4%.
Is Pangaea Oncology's EBIT per Share too high?
Pangaea Oncology's current EBIT per Share is €-0.11. Based on the distribution chart, Pangaea Oncology ranks #126 out of 165 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #126 out of 165 companies for EBIT per Share. This places Pangaea Oncology in the lower half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current EBIT per Share is €-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.17, compared to a current price of €1.50 — trading 30.9% below its estimated fair value. The current EBIT per Share is €-0.11. Pangaea Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current EBIT per Share is €-0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.50 is trading 30.9% below its estimated GF Value™ of €2.17.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
EBIT per Share: €-0.11
GF Value™: €2.17 vs. price of €1.50 (30.9% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
61GF Score
Get the complete analysis for XMAD:PANG
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
